We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

406 hedge funds and large institutions have $17.3B invested in Alexion Pharmaceuticals in 2013 Q2 according to their latest regulatory filings, with 406 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more call options, than puts

Call options by funds: $149M | Put options by funds: $97.1M

Holders
406
Holders Change
+406
Holders Change %
–
% of All Funds
13.25%
Holding in Top 10
6
Holding in Top 10 Change
+6
Holding in Top 10 Change %
% of All Funds
0.2%
New
406
Increased
–
Reduced
–
Closed
–
Calls
$149M
Puts
$97.1M
Net Calls
+$51.9M
Net Calls Change
+$51.9M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Capital Research Global Investors
1
Capital Research Global Investors
California
$1.98B +$2.06B +21,428,100 New
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$1.56B +$1.63B +16,919,077 New
Fidelity Investments
3
Fidelity Investments
Massachusetts
$1.55B +$1.62B +16,782,828 New
Jennison Associates
4
Jennison Associates
New York
$891M +$931M +9,658,548 New
Vanguard Group
5
Vanguard Group
Pennsylvania
$842M +$880M +9,129,033 New
Sands Capital Management
6
Sands Capital Management
Virginia
$777M +$812M +8,424,567 New
State Street
7
State Street
Massachusetts
$715M +$747M +7,754,992 New
Wells Fargo
8
Wells Fargo
California
$548M +$573M +5,941,192 New
Viking Global Investors
9
Viking Global Investors
Connecticut
$511M +$534M +5,544,949 New
BIT
10
BlackRock Institutional Trust
California
$476M +$498M +5,165,833 New
Winslow Capital Management
11
Winslow Capital Management
Minnesota
$386M +$403M +4,186,090 New
JP Morgan Chase
12
JP Morgan Chase
New York
$348M +$363M +3,769,473 New
BFA
13
BlackRock Fund Advisors
California
$325M +$340M +3,527,133 New
American Century Companies
14
American Century Companies
Missouri
$297M +$311M +3,222,708 New
Bank of New York Mellon
15
Bank of New York Mellon
New York
$265M +$277M +2,876,380 New
Northern Trust
16
Northern Trust
Illinois
$255M +$266M +2,759,904 New
TCIM
17
TIAA CREF Investment Management
New York
$247M +$258M +2,676,282 New
Ameriprise
18
Ameriprise
Minnesota
$223M +$233M +2,420,110 New
Invesco
19
Invesco
Georgia
$213M +$223M +2,309,286 New
Artisan Partners
20
Artisan Partners
Wisconsin
$190M +$199M +2,060,800 New
JHIU
21
Janus Henderson Investors US
Colorado
$173M +$180M +1,871,394 New
Norges Bank
22
Norges Bank
Norway
$137M +$143M +1,481,097 New
BG
23
BlackRock Group
United Kingdom
$132M +$138M +1,431,753 New
Geode Capital Management
24
Geode Capital Management
Massachusetts
$123M +$129M +1,335,034 New
DCP
25
DSM Capital Partners
Florida
$122M +$127M +1,321,177 New
1
2 3 4 5

ALXN Hedge Fund Activity: Q2 2013 in Review

406 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q2 2013, worth a combined $17.3B.

Buyers outnumbered sellers: 406 funds opened new ALXN positions and 0 closed out — a net gain of 406 holders — while 0 added to existing stakes and 0 trimmed.

  • 406 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $17.3B of Alexion Pharmaceuticals stock for Q2 2013.
  • 406 funds opened new Alexion Pharmaceuticals positions in Q2 2013 and 0 closed out, a net change of +406 holders.

Based on aggregated 13F filings for Q2 2013.